Source:http://linkedlifedata.com/resource/pubmed/id/17680023
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2007-9-19
|
| pubmed:abstractText |
The purpose of this study was to analyze the prognostic significance of early lymphocyte recovery after autologous SCT (ASCT) in the setting of routine post transplant administration of GM-CSF in patients with non-Hodgkin's lymphoma (NHL). This is a single institution retrospective comparative outcome analysis in a cohort of 268 relapsed chemosensitive NHL patients divided into two groups (early and late lymphocyte recovery) based on absolute lymphocyte counts (ALC) obtained on post transplant day +15 (ALC > or = 500, n=151 (56%) and ALC < 500, n=117 (44%)). Patient's characteristics were well-balanced between the two groups with regard to age, sex, preparative regimen, prior therapy, time from diagnosis to transplant and number of CD34+ cells infused. Post transplant complications were comparable in the two groups. Late lymphocyte recovery (ALC < 500 on day +15) was independently associated with a delay in platelet recovery (29 vs 21 days, P=0.0003) in patients who have not received pre-transplant rituximab. With a median follow-up of 22 months, no associations between early lymphocyte recovery and improvement of disease-free and overall survival were observed for either low- or intermediate-grade NHL. In conclusion, in this large single-centered retrospective analysis, where patients received routine post transplant GM-CSF, early lymphocyte recovery was not associated with favorable outcomes.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
40
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
671-5
|
| pubmed:meshHeading |
pubmed-meshheading:17680023-Adult,
pubmed-meshheading:17680023-Aged,
pubmed-meshheading:17680023-Antigens, CD,
pubmed-meshheading:17680023-Antigens, CD34,
pubmed-meshheading:17680023-Female,
pubmed-meshheading:17680023-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:17680023-Humans,
pubmed-meshheading:17680023-Lymphocyte Count,
pubmed-meshheading:17680023-Lymphocytes,
pubmed-meshheading:17680023-Lymphoma, Non-Hodgkin,
pubmed-meshheading:17680023-Male,
pubmed-meshheading:17680023-Middle Aged,
pubmed-meshheading:17680023-Neoplasm Staging,
pubmed-meshheading:17680023-Neutropenia,
pubmed-meshheading:17680023-Platelet Transfusion,
pubmed-meshheading:17680023-Prognosis,
pubmed-meshheading:17680023-Retrospective Studies,
pubmed-meshheading:17680023-Stem Cell Transplantation,
pubmed-meshheading:17680023-Transplantation, Autologous,
pubmed-meshheading:17680023-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Division of Oncology, Department of Medicine, Section of Bone Marrow Transplantation and Leukemia, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|